Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LCUJ | ISIN: FR0010331421 | Ticker-Symbol: IDD
Tradegate
11.08.25 | 11:00
1,848 Euro
+1,43 % +0,026
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNATE PHARMA SA Chart 1 Jahr
5-Tage-Chart
INNATE PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,8081,82416:14
1,7981,83416:14

Aktuelle News zur INNATE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.08.Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025263Regulatory news: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General...
► Artikel lesen
29.07.Innate Pharma SA - 6-K, Report of foreign issuer1
29.07.Innate Pharma SA: Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference293Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the company's CEO Jonathan Dickinson and COO Yannis Morel will participate...
► Artikel lesen
28.07.Innate Pharma: BTIG startet Coverage mit Kaufempfehlung und sieht fast 300 % Kurspotenzial2
28.07.Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential1
07.07.Innate Pharma SA - 6-K, Report of foreign issuer3
INNATE PHARMA Aktie jetzt für 0€ handeln
04.07.Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025314Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General...
► Artikel lesen
17.06.Innate Pharma SA: Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences327Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will participate in the upcoming investor conferences...
► Artikel lesen
13.06.Innate Pharma SA - 6-K, Report of foreign issuer2
13.06.Innate Pharma SA: Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress310Preclinical data from IPH6501, Innate's proprietary ANKET targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL)...
► Artikel lesen
27.05.Innate Pharma SA - 6-K, Report of foreign issuer4
27.05.Innate Pharma SA: Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences502Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the upcoming...
► Artikel lesen
23.05.Innate Pharma SA: Outcome of Innate Pharma's 2025 Annual General Meeting350Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took...
► Artikel lesen
23.05.Innate Pharma SA: Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides396Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from...
► Artikel lesen
19.05.Innate Pharma SA - 6-K, Report of foreign issuer1
19.05.Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting305Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides Trial in Progress poster on IPH4502, Innate's differentiated ADC in development in advanced...
► Artikel lesen
15.05.Innate Pharma SA: Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress435Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET targeting CD20 B cells currently...
► Artikel lesen
13.05.Innate Pharma S.A. reports Q1 results2
13.05.Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook22
13.05.Innate Pharma Q1 Revenue Declines, Stock Down2
Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1